Results 141 to 150 of about 95,860 (291)

Cyclosporine: Is There a Role in Inflammatory Bowel Disease? [PDF]

, 1988
Richard N. Fedorak
openalex   +1 more source

Postauricular Skin Mycobiome Profiles in Atopic Dermatitis Treated With Dupilumab or Cyclosporine A: A Descriptive Case Series

The Journal of Dermatology, EarlyView.
ABSTRACT Atopic dermatitis (AD) essentially exhibits dysbiosis of skin fungal microbiome, mycobiome, characterized by depletion of Malassezia. The effects of recent systemic therapies for AD on skin mycobiome were not understood enough. We examined changes of skin mycobiome before and after systemic treatments with anti‐IL‐4Rα antibody (dupilumab: DUP)
Yuta Koike, Hitomi Morisaki, Daisuke Motooka, Mai Matsumoto, Motoi Takenaka, Hiroyuki Murota   +5 more
wiley   +1 more source

Comparing the effectiveness and drug persistence of methotrexate, cyclosporine, and acitretin for psoriasis. [PDF]

Int J Womens Dermatol
Chaiyabutr C, Paringkarn T, Silpa-Archa N, Wongpraprarut C, Chularojanamontri L.   +4 more
europepmc   +1 more source

Charge-density study on cyclosporine A [PDF]

, 2009
S. K. J. Johnas, Birger Dittrich, Alke Meents, M. Messerschmidt, E. Weckert   +4 more
openalex   +1 more source

Long‐Term, Site‐Specific Effectiveness of Tralokinumab in Atopic Dermatitis: A 72‐Week Real‐World Study

The Journal of Dermatology, EarlyView.
ABSTRACT Tralokinumab, an anti‐IL‐13 antibody, is effective for atopic dermatitis (AD); however, its long‐term (> 1 year) effectiveness specific to each anatomical site is unknown in real‐world settings. To evaluate 72‐week effectiveness of tralokinumab on different anatomical sites in AD, we studied 208 patients with moderate‐to‐severe AD treated with
Mizuki Shiba, Teppei Hagino, Akihiko Uchiyama, Hidehisa Saeki, Eita Fujimoto, Sei‐ichiro Motegi, Naoko Kanda   +6 more
wiley   +1 more source

Evaluating rituximab against cyclophosphamide or cyclosporine in idiopathic membranous nephropathy: a meta-analysis. [PDF]

Eur J Med Res
Zhang Y, Chen H, Zhang H, Huang Y.
europepmc   +1 more source

Effect of hematocrit on cyclosporine (cyclosporin A) in whole blood and plasma of renal-transplant patients. [PDF]

, 1985
T G Rosano
openalex   +1 more source

Outcome parameters in studies investigating dry eye disease: A systematic literature review

Acta Ophthalmologica, EarlyView.
Abstract The development of effective therapeutics for dry eye disease (DED) is challenging due to its complex pathophysiology, heterogeneous patient presentation and the significant failure rate of previous clinical development programs. This underlines the importance of the selection of appropriate endpoints for clinical trials.
Viktoria Pai, Doreen Schmidl, Liudmyla Petric, Patrick Janku, Theresa Lindner, Ulrich Graf, Jacqueline Chua, Leopold Schmetterer, Gerhard Garhöfer   +8 more
wiley   +1 more source

Acute fibrinous and organizing pneumonia after bone marrow transplantation, an underrecognized, severe condition. [PDF]

Hematol Transfus Cell Ther
Cortez AC, Seiwald MCN, da Fonseca ARBM, Ferreira AM, Pogorzelski G, Testagrossa LA, Novis Y, Costa AN.   +7 more
europepmc   +1 more source

Monovalent mannose‐glycoconjugates of sulforaphane reprogram human dendritic cells via NFATc1 to induce immune tolerance under inflammatory conditions

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Immune tolerance prevents inflammation and autoimmunity, with dendritic cells (DCs) playing a key role. Reprogramming DCs towards a tolerogenic state represents a promising therapeutic strategy. Sulforaphane (SFN) has known immunomodulatory effects, but its clinical application is limited by poor stability and ...
María Elena Angarita‐Planchez, Camila Leiva‐Castro, Ana M. Múnera‐Rodríguez, Macarena Martínez‐Bailén, Ana T. Carmona, Soledad López‐Enríquez, Francisca Palomares   +6 more
wiley   +1 more source